Risk models based on non-cognitive measures may identify presymptomatic Alzheimer's disease

Jingjing **Yang**, PhD[1]*; Shahram **Oveisgharan**, MD[2]; Xizhu **Liu**[3]; Robert S **Wilson**, PhD[2]; David A **Bennett**, MD[2]; Aron S **Buchman**, MD[2]

1. Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory University School of Medicine, 615 Michael St, Atlanta, GA, 30322, USA;

2. Rush Alzheimer's Disease Center, Rush University Medicine Center, Chicago, IL, 60612, USA;

3. Quantitative Theory and Methods program, College of Arts and Sciences, Emory University, Atlanta, GA, 30322, USA

* Correspondence author: JY; jingjing.yang@emory.edu ; 001-404-727-3481.

Authorship contributions:

- Jingjing Yang: Drafting/revision of the manuscript for content, including medical writing for content; Study design; Analysis or interpretation of data

- Shahram Oveisgharan: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

- Xizhu Liu: Analysis or interpretation of data

- Robert S Wilson: Major role in the acquisition of data

- David A Bennett: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

- Aron S Buchman: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

ABSTRACT

Background: Alzheimer's disease is a progressive disorder without a cure. Developing

risk prediction models for detecting presymptomatic Alzheimer's disease using non-

cognitive measures is necessary to enable early interventions.

Objective: Examine if non-cognitive metrics alone can be used to construct risk models

to identify adults at risk for Alzheimer's dementia and cognitive impairment.

Methods: Clinical data from older adults without dementia from the Memory and Aging

Project (MAP, n=1179) and Religious Orders Study (ROS, n=1103) were analyzed

using Cox proportional hazard models to develop risk prediction models for Alzheimer's

dementia and cognitive impairment. Models using only non-cognitive covariates were

compared to models that added cognitive covariates. All models were trained in MAP,

tested in ROS, and evaluated by the AUC of ROC curve.

Results: Models based on non-cognitive covariates alone achieved AUC (0.800,0.785)

for predicting Alzheimer's dementia (3,5) years from baseline. Including additional

cognitive covariates improved AUC to (0.916,0.881). A model with a single covariate of

composite cognition score achieved AUC (0.905,0.863)**.** Models based on non-cognitive

covariates alone achieved AUC (0.717,0.714) for predicting cognitive impairment (3,5)

years from baseline. Including additional cognitive covariates improved AUC to

(0.783,0.770). A model with a single covariate of composite cognition score achieved

AUC (0.754,0.730).

Conclusion: Risk models based on non-cognitive metrics predict both Alzheimer's

dementia and cognitive impairment. However, non-cognitive covariates do not provide

incremental predictivity for models that include cognitive metrics in predicting

Alzheimer's dementia, but do in models predicting cognitive impairment. Further

improved risk prediction models for cognitive impairment are needed.

Keywords: Alzheimer's disease, Cognitive aging, Mild cognitive impairment, Cohort

study, Cox proportional hazard model

INTRODUCTION

Alzheimer's disease is a progressive disorder that develops over years. An asymptomatic stage during which Alzheimer's disease pathology (AD) accumulates is followed by mild cognitive impairment (MCI), while dementia occurs later [1-3]. Alzheimer's disease is heterogeneous; most demented individuals transition through all three clinical stages i.e., from no cognitive impairment (NCI) to MCI followed by dementia. Some individual's transition directly from NCI to dementia. On the other hand, some never progress beyond MCI and 1/3 with NCI prior to death also show pathologic AD at death.

Early detection of adults with normal cognition at risk for Alzheimer's disease cognitive traits is crucial for early targeted treatments [4, 5]. This underscores the widespread efforts to develop risk prediction models for detecting presymptomatic Alzheimer's disease. Yet, using cognitive test scores as a predictor for the incident cognitive impairment (MCI or Alzheimer's dementia) may be statistically problematic as the same test scores may be used as model predictors as well as for the diagnostic characterization of cognitive status, which is the outcome the model seeks to identify. Moreover, comprehensive cognitive testing requires in-person testing that is not widely available. This highlights the potential benefits of identifying non-cognitive covariates that may be obtained remotely and contain predictive information to identify cognitively normal adults at risk for incident cognitive impairment and Alzheimer's dementia.

Alzheimer's disease is a complex disorder that not only negatively affects cognition, but also adversely affects other important non-cognitive aging phenotypes [6]. For example, accumulation of AD is associated with body mass index (BMI) decline or

impaired motor function that may precede and predict incident cognitive impairment and

Alzheimer's dementia [7-11]. Gait velocity and variability are associated with cognitive

decline and gait is shown as a proxy for overall health and as an index of cognitive

decline [12]. These data suggest that developing a risk profile based on non-cognitive

covariates may facilitate the identification of at risk adults during the earliest stages of

Alzheimer's disease.

To test this hypothesis, it is crucial to examine non-cognitive and cognitive

covariates alone and together to compare model performance and identify the optimal

covariates for predicting incident Alzheimer's dementia and incident cognitive

impairment. This study used clinical data from older adults without dementia

participating in one of two prospective community-based cohort studies of aging, Rush

Memory and Aging Project (MAP) and the Religious Orders Study (ROS) [13]. We

trained models in MAP and validated model prediction performance in ROS.

MATERIALS AND METHODS

Participants

Participants were community dwelling older persons enrolled in one of two

ongoing cohort studies of aging and dementia, MAP (n=1179) and ROS (n=1103).

Participants were enrolled without known dementia; 1742 with NCI and 540 with MCI at

enrollment (**Tables S1-S2**). All agreed to annual clinical evaluations and autopsy at the

time of death. The duration of follow up for participants ranged from 2 to 26 years, with

a median of 8-year and standard deviation 5.42 (**Supplementary Figure 1**). Both

cohorts employ a harmonized data collection battery administered by the same

research assistants facilitating joint analyses.

Cognitive Assessment and Diagnoses

Detailed structured clinical examinations were administered annually to

participants in both studies. The neuropsychological battery includes 17 tests that

assess five domains of cognitive ability. Raw test scores were standardized per test

using baseline means and standard deviations (SDs) of both cohorts; the resulting Z-

scores were then averaged across the 17 cognitive tests to derive a summary

composite cognition score and scores for five cognitive abilities including: episodic

memory, semantic memory, working memory, visuospatial abilities, and perceptual

speed.

A neuropsychologist and a neurologist with expertise in dementia reviewed

annual cognitive testing and classified cognitive status of participants as NCI, MCI,

Alzheimer's dementia, or other dementias according to established NIA-AA criteria [13-

16]. We excluded individuals who developed non-Alzheimer's dementia from these

analyses.

This study first examined models which predicted transition from no dementia

(NCI or MCI) to Alzheimer's dementia (**Fig 1, Row 1**). Second, we examined models

which predicted transition from NCI to Alzheimer's dementia (**Fig 1, Row 2**). Third, we

studied the outcome of incident cognitive impairment which was defined by the first

annual assessment when an individual who was previously cognitively normal (NCI)

transitioned to cognitive impairment manifested as either MCI or Alzheimer's dementia

(**Fig 1, Row 3**).

Other Clinical Covariates

Five groups of clinical variables (a total of 57) were considered potential

covariates in the Cox proportional hazard regression models for risk prediction (**Table 1;**

Tables S3-S4) — i) *Common Alzheimer's disease risk factors* including age, sex,

education, Mini Mental State Exam (MMSE) score [17] and *APOE* E4 allele; ii) *Health*

measures such as blood pressure, depression, and cardiovascular diseases; iii)

Medication usage such as lipid lowering medications, and antidepressants; iv) *Variables*

uniquely profiled by MAP/ROS such as composite cognition scores based on 17

cognitive tests, self-reported physical activity and social network size [13]; v) *Motor and*

sleep metrics such as dexterity, hand strength, gait function, four parkinsonian signs

[16], and four self-reported variables about sleep quality and duration [15].

These 57 clinical covariates were selected by excluding variables with a high

proportion of missing values (>20%) and those that were highly correlated with other

clinical variables (correlation>0.95). Missing baseline values of longitudinal variables

were imputed from the corresponding values at participant's nearest past visit. A total of

345 individuals with missing cross-sectional variables were excluded, leaving n=1179

MAP and n=1103 ROS participants for these analyses. A heat map showing the

correlations of the covariates examined in these models is shown in **Supplementary**

Figure 2.

Analytic Approach

The annual cognitive status diagnosis and the follow up year were used to identify the first occurrence of Alzheimer's dementia or incident cognitive impairment. For each participant, the year of enrollment is considered as baseline (time 0), the year of first diagnosis of Alzheimer's dementia and cognitive impairment (MCI or Alzheimer's dementia) is considered as the time when the event occurs (incident Alzheimer's dementia or incident cognitive impairment), and the last visit of participants without the considered event during all follow-ups is considered as the right censored time for living participants or the time of death for dead participants. Less than 10% of participants developing Alzheimer's dementia progressed directly from NCI to Alzheimer's dementia. Sample size distributions with respect to cognitive status at baseline and the cognition event types are included in **Tables S1-S2**.

We fit separate Cox proportional hazard risk prediction models [18-21] for incident Alzheimer's dementia or incident cognitive impairment while accounting for the competing risk of death. In the first stage of our analysis, we examined the prediction accuracy of using non-cognitive covariates alone in the Cox models (Model A). Then, we examined if adding cognitive covariates improved the model accuracy assessed. Model performance, i.e., discrimination was evaluated by the prediction area under curve (AUC) values of receiver operating characteristic curve (ROC) [22] for the risk of developing Alzheimer's dementia and cognitive impairment 3, 5 years from the analytic baseline. AUC is equal to the probability that a classifier will rank a randomly chosen individual with the outcome of interest (event or case) higher than a randomly chosen individual without impaired cognition (control), assuming 'case' ranks higher than

'control' [22]. That is, the derived risk prediction model with higher AUC is expected to

predict the risk of developing Alzheimer's dementia or cognition impairment with higher

accuracy.

Next, we added the MMSE score (Model B) and then repeated the model a third

time adding the composite cognition score (Model C). In further analyses, we sought to

isolate the prediction accuracy of different combinations of cognitive metrics alone

including: composite cognition score (Model D), MMSE score (Model E), as well as the

five cognitive ability scores (Model F) used for its construction and the 17 individual

cognitive test scores (Model G). Since all covariates were standardized, the magnitudes

of covariate coefficients in the Cox models are comparable with respect to predictivity.

By selecting a risk score threshold corresponding the highest overall

classification accuracy (the proportion of correct discriminations in test ROS samples),

we compared the overall classification, sensitivity (the proportion of true positive

predictions in all test cases, i.e., true positive fraction), and specificity (the proportion of

true negative predictions in all test controls, i.e., 1 – false positive fraction), for Models

A-D. Samples with risk scores greater than the selected threshold were predicted as

positives or otherwise negatives. The sensitivity and specificity corresponding to a

selected risk score threshold reflect risk model performance at one point in the ROC

curves.

Backward variable selection was implemented during the training of Cox models

that consider more than one covariate. In particular, we started with the full Cox model

with all potential covariates; proceeded with a temporary Cox model by excluding the

covariate with the least significant p-value; compared their C-statistics (equivalent to

AUC) and conducted ANOVA test to examine if the temporary Cox model would be

improved over the current Cox model; accepted the temporary Cox model if the C-

statistic was improved in the temporary Cox model or otherwise the ANOVA test p-

value<0.05. We continued to exclude the covariate with the least significant p-value

from the accepted Cox model until the proposed temporary Cox model was not

accepted or when there was only one covariate remained in the model.

For Alzheimer's dementia, we first considered all individuals including adults with

either NCI or MCI at baseline, and then only individuals with NCI at baseline. Modeling

incident cognitive impairment considered only individuals with NCI at baseline.

All Cox models were trained using data from MAP participants and validated (i.e., tested)

with data from ROS participants [23]. We tested the respective AUC improvement in 3,

5 years of two models by a nonparametric test that accounts for the correlated nature of

the ROC curves [24]. We also evaluated the prediction accuracy, sensitivity, and

specificity by choosing the prediction risk score threshold with respect to the highest

overall accuracy.

Association Tests between Predicted Risk Scores of Alzheimer's Dementia and

Brain Pathologies

We investigated the association between predicted risk scores (by the full Model

C) of NCI/MCI samples developing Alzheimer's dementia in 3, 5 years in our test ROS

cohort and Alzheimer's disease related dementia (ADRD) neurodegenerative and

cerebrovascular disease brain pathologies — Amyloid, Tangles, Global AD pathology

(Gpath), NIA Reagan pathology (NIA), Lewy body pathology (LewyBody), Hippocampal

Sclerosis (Hippo), TDP-43, Macroinfarct (Macro), Microinfarct (Micro), Atherosclerosis

(Arthero), Arteriolosclerosis (Arteriol), Cerebral amyloid angiopathy (CAA). Correlation

tests were conducted for quantitative pathologies (Amyloid, Tangles, and Gpath), and

two-sample t-tests were conducted for the remain dichotomized pathologies (present vs.

not present). Only deceased ROS participants who underwent autopsy and had profiled

pathologies were tested (~50%).

Standard Protocol Approvals, Registrations, and Patient Consents

Both MAP and ROS studies were approved by an Institutional Review Board of

Rush University Medical Center. Written informed consent was obtained from all study

participants as was an Anatomical Gift Act for organ donation.

Data Availability

All data analyzed in this study are de-identified and available to any qualified

investigator with application through the Rush Alzheimer's Disease Center Research

Resource Sharing Hub, https://www.radc.rush.edu, which has descriptions of the

studies and available data.

RESULTS

Risk Models Predicting Alzheimer's Dementia

Overall model performance: Cox proportional hazard model trained using only non-

cognitive covariates showed good model performance [25] for predicting Alzheimer's

dementia 3, 5 years from baseline (**Fig 1, Row 1 Model A**). Stepwise addition of the

cognitive covariate MMSE and then composite cognition yielded further significant

improvement in the initial model performance of using only non-cognitive covariates

(**Fig 1, Row 1 Model B & Model C).** The performance accuracy of the full model

including non-cognitive covariates, MMSE and composite cognition score was similar to

the performance of a model including composite cognition score alone (Model D) for

Year 3. The full model outperformed Model D for Year 5 (**Fig 1, Row 1 Model C &**

Model D).

<u>Important clinical predictors:</u> As expected, composite cognition score had the largest

protective effect size when it was considered in the full model (**Fig 2, Row 1 Model C**).

Similarly, in the model including non-cognitive and MMSE covariates (**Supplementary**

Table 5), we observed that MMSE had the largest protective effect size, followed by

hand strength and *APOE* E2. In contrast, increasing age and the presence of *APOE* E4

had the largest effect size for increased risk of Alzheimer's dementia, when only non-

cognitive covariates were considered in Model A.

<u>Cognitive metrics as predictors:</u> To better understand the role of cognitive measures in

predicting Alzheimer's dementia, we compared the model performance of different

combinations of cognitive metrics alone for predicting Alzheimer's dementia

(**Supplementary Figure 3 Row 1)**. Model performance for MMSE predicting

Alzheimer's dementia (**Supplementary Figure 3, Row 1 Model E**) was comparable

with a model based only on non-cognitive measures (**Fig 1, Row 1 Model A**). The

various cognitive metrics based on 17 cognitive tests alone (**Supplementary Figure 3,**

Row 1 Model F and Model G) showed similar excellent model performance that was

not improved by the addition of the non-cognitive covariates or MMSE. Of all the

cognitive indices, episodic memory had the largest protective effect size

(**Supplementary Figure 4, Row 1**).

Exclude baseline MCI patients: Analyses of individuals without dementia include adults

with NCI or MCI at baseline. In further analyses, we restricted our analyses only to

individuals with baseline NCI to see if the same trends were observed despite the

truncated heterogeneity of cognitive function by exclusion of individuals with baseline

MCI. Model performance for non-cognitive covariates for adults with baseline NCI alone

was similar to models that also included adults with baseline MCI (**Fig 1, Row 2 Model**

A versus Row 1 Model A). There was improved model performance when cognitive

covariates MMSE or composite cognition scores were added to the non-cognitive

covariates (**Fig 1, Row 2 Model B and Model C**). Yet, improvement in model

performance for predicting dementia in adults with baseline NCI alone was less marked

compared to models that consider adults with baseline NCI or MCI (**Fig 1, Row 2 vs.**

Row 1, Model B and Model C).

Classification accuracy: By comparing the prediction accuracy, sensitivity, and

specificity corresponding to a selected risk score threshold ensures the highest overall

accuracy per model for Models A-D. The pattern in **Table 2** was similar to **Fig 1, Row 1**

and Row 2. That is, the full Model C performed the best with overall accuracy for Year

(3, 5), that outperformed Model A and Model B for Year (3, 5) when composite cognition

was not considered, and outperformed Model D for Year 5 when only composite

cognition was considered. The full Model C performed comparably with Model D for

Year 3.

Association between Predicted Risk Scores for Alzheimer's Dementia and Mixed-

Brain Pathologies

Accumulating evidence suggests that clinical Alzheimer's dementia is most

commonly associated with mixed brain pathologies. We examined the association

between predicted risk scores of Alzheimer's dementia by the full risk model for

NCI/MCI samples (**Fig 1, Row 1, Model C**) and 12 different postmortem indices of

ADRD pathologies in our test ROS cohort. Using the significance threshold with

Bonferroni correction for testing 12 pathologies (-log10(0.05/12)), we found that the risk

scores predicted by the full Model C for developing Alzheimer's dementia in 3, 5 years

were associated with 5 out of 12 ADRD pathologies, including both neurodegenerative

pathologies (Tangles, global AD pathology, NIA Reagan) and cerebrovascular disease

pathologies (Atherosclerosis, Cerebral amyloid angiopathy). These results

(**Supplemental Figure 5**) showed that the risk scores predicted by our derived models

were significantly associated with mixed-brain pathologies.

Risk Models Predicting Cognitive Impairment

Overall model performance: Cox proportional hazard model trained using only non-

cognitive covariates showed adequate model performance [25] for predicting cognitive

impairment 3 and 5 years from baseline (**Fig 1, Row 3 Model A**). Yet, discrimination for

predicting cognitive impairment was lower than the model predictions of Alzheimer's

dementia (**Fig 1, Row 3 vs. Row 1 Model A**). Stepwise addition of MMSE and then

composite cognition yielded further improvement in the initial model performance (**Fig 1,**

Row 3 Model B and Model C)**.** AUC for all models predicting cognitive impairment

were lower than models predicting Alzheimer's dementia (**Fig 1 and Supplementary**

Figure 3). The performance accuracy of the full model that included non-cognitive,

MMSE and composite cognition score showed better model performance compared to

models with the composite cognition alone (**Fig 1, Row 3 Model C vs. Model D**).

Important clinical predictors: By examining the effect sizes in the Cox model using non-

cognitive and MMSE covariates (**Fig2; Supplementary Table 5**), we observed that

MMSE had the largest protective effect size and age had the largest effect size for

increased risk of cognitive impairment. Composite cognition still had the largest

protective effect for reducing the risk of cognitive impairment when it was considered in

the full model. We observed that age and *APOE* E4 were associated with an increased

risk of both Alzheimer's dementia and cognitive impairment. Better motor function was

associated with reduced risk of Alzheimer' dementia (hand strength and gait) and

cognitive impairment (hand strength and parkinsonism) (**Fig 2; Supplementary Table**

5).

Cognitive function metrics: Next, we compared model performance for several cognitive

metrics alone for predicting cognitive impairment. Model performance for MMSE alone

(**Supplementary Figure 3, Row3 Model E**) was poor and significantly lower than a

model based on all the non-cognitive covariates together (**Fig 1, Row 3 Model A**).

Models using scores of five cognitive abilities (**Supplementary Figure 3, Row3 Model**

F) or using the 17 individual cognitive test scores (**Supplementary Figure 3, Row3**

Model G) had comparable prediction AUC as the model using composite cognition

alone (**Supplementary Figure 3, Row3 Model D**). These results together with the joint

modeling of cognitive and non-cognitive covariates (**Fig1, Row 3**) show that non-

cognitive clinical covariates contain additional predictive information for predicting

cognitive impairment not be accounted for by using cognitive covariates alone.

Classification accuracy: By comparing the prediction accuracy, sensitivity, and

specificity corresponding to a selected risk score threshold ensures the highest overall

accuracy per model for Models A-D (**Table 2**). These models show a similar pattern to

Fig 1, Row 3. That is, the full Model C performed the best with the highest overall

accuracy and specificity for Year (3, 5) performing better than models that did not

include global cognition score (A and B) or a model with global cognition score alone

(Model D). So, joint models of non-cognitive and cognitive measures provide better

predictions of cognitive impairment than cognitive measures alone.

Discussion

Risk models for incident Alzheimer's dementia

This study used a wide range of non-cognitive covariates to construct

multifactorial risk models that as hypothesized yielded good model performance for

predicting incident Alzheimer's dementia. An important aspect of this study was that we

examined model performance achieved by non-cognitive covariates and cognitive

function metrics alone and jointly in adults with no dementia. This analytic approach

allows us to isolate the potential improvement in model performance due to non-

cognitive or cognitive covariates. Our results highlight the effectiveness of cognitive

measures alone in predicting Alzheimer's dementia.

While risk models like the Framingham Risk Score have been developed to

predict vascular events [26], there is no widely accepted risk model for the prediction of

Alzheimer's dementia or cognitive impairment [5, 27-32] (**Supplementary Table 6**). In

addition, the aging field has not converged on a parsimonious set of dementia risk

factors that must be included when developing risk models for cognitive outcomes. Thus,

many studies have included cognitive metrics together with non-cognitive covariates [33,

34] and many other studies have not included cognitive measures [5, 27, 28, 30, 35].

Given the varied covariates employed in prior publications, it is not surprising that model

discrimination has ranged from an AUC of 0.55 to 0.95 for predicting Alzheimer's

dementia. However, even studies reporting models with adequate discrimination have

not usually replicated these findings in independent cohorts. Moreover, there has not

been a systematic effort to clarify the independent roles of non-cognitive versus

cognitive metrics for predicting Alzheimer's dementia as well as consensus about

whether to include cognitive measures as both predictors and outcome in the same

models. Nonetheless, review of these past studies suggests that overall, model

performance for predicting Alzheimer's dementia in very old adults was lower when risk

models were based on non-cognitive metrics alone [28].

Our results, validated in an independent cohort, suggest that risk models using

non-cognitive covariates show good model performance and predict Alzheimer's

dementia. We also showed that this good performance was further improved by adding

cognitive scores. Yet, further analyses showed that the risk models based on composite

cognitive metrics alone achieved better model performance than the model based on

non-cognitive covariates and MMSE for Alzheimer's dementia (**Fig 1, Row 1**). By

restricting our modeling only to adults with NCI, we showed that non-cognitive variables

add additional predictive information that cannot be accounted for by the composite

cognitive scores alone for predicting Alzheimer's dementia (**Fig 1, Row 2**). These

results may have important clinical consequences for public health efforts to identify

adults with presymptomatic Alzheimer's disease, i.e., NCI at risk for future dementia.

Further work is needed to identify non-cognitive covariates or AD biomarkers that may

improve risk models in adults with NCI at the earliest stages of Alzheimer's disease.

Risk models for incident cognitive impairment

Transition from NCI to MCI, an earlier stage in the trajectory of Alzheimer's

disease, occurred in almost all participants (>90%) who developed Alzheimer's

dementia in MAP/ROS studies. Since the biology underlying earlier and later stages of

Alzheimer's disease may vary, their respective risk models may be different [3].

Compared to studying Alzheimer's dementia, larger sample size and wider range of

clinical variables are needed for studying cognitive impairment that includes transition

from NCI to either MCI or Alzheimer's dementia. Thus, there are far fewer studies which

have developed risk models for predicting cognitive impairment as compared to

dementia and even fewer have validated findings in independent samples. Model

performances reported for predicting cognitive impairment have varied widely

(**Supplementary Table 7**) [34, 36-38]. We are unaware of studies that isolated the

independent and joint contributions of non-cognitive and cognitive metrics for model

discrimination of incident cognitive impairment.

Our study found that risk models for cognitive impairment based on only non-

cognitive covariates showed adequate model performance but consistently poorer than

prediction models for Alzheimer's dementia (**Fig 1 Row 2 vs Row 3**). While adding

cognitive covariates in addition to non-cognitive covariates improved model

performance predicting cognitive impairment, overall performance never equaled model

performance for predicting Alzheimer's dementia. These findings highlight the

importance of further studies to identify additional clinical metrics or biomarkers to

improve the prediction of cognitive impairment.

Risk models for cognitive impairment versus Alzheimer's dementia

An additional strength of the current study design is that we compared the

performances of models predicting cognitive impairment and Alzheimer's dementia

using the same covariates and individuals with NCI at baseline. In addition, we validated

our results in an independent sample of older adults. Model performance for predicting

Alzheimer's dementia was much better than models predicting cognitive impairment.

These findings may derive from the differences in the symptoms and diagnoses of MCI

versus Alzheimer's dementia. That is, discriminating symptoms of Alzheimer's dementia

from NCI/MCI is generally much easier than discriminating symptoms of MCI from NCI.

There is more random error and instability in the diagnosis of MCI compared to

dementia. Many prior studies have reported lower sensitivity and specificity for cognitive

instruments used to identify MCI compared to Alzheimer's dementia [39]. Individuals

with MCI show more fluctuations between NCI and MCI during repeated cognitive

testing. In contrast, once individuals receive a diagnosis of dementia, they are less likely

to revert back to NCI/MCI on repeated testing.

Yet, varied model performance for predicting cognitive impairment and

Alzheimer's dementia may inform differences in the respective biology underlying these

Alzheimer's clinical traits [40]. Additionally, the associations between a specific risk

factor with dementia may vary over time. For example, high BMI in mid-life may be

related to an increased risk of dementia, while high BMI in much older adults may be

related to decreased risk of dementia [41]. Analogously, in earlier stages of Alzheimer's

disease, the burden and location of AD may lead to impaired non-cognitive function like

motor function to a greater extent than cognition. In contrast, during its later stages the

widespread accumulation of AD throughout cognitive brain regions may have a larger

pervasive negative impact on cognition. While cognitive and motor decline in older adult

are both commonly associated with mixed-brain pathologies, different combinations of

pathologies may be associated with cognitive and motor phenotypes in the same

individual [6, 11]. This might account for better performance achieved by cognitive

metrics for Alzheimer's dementia and the lack of incremental validity of non-cognitive

covariates when considered together with cognitive metrics for Alzheimer's dementia.

This might also account for the incremental predictivity of non-cognitive covariates in

addition to cognitive metrics for incident cognitive impairment.

Implications of the current findings

The reconceptualization of Alzheimer's disease as a chronic progressive disorder

that develops over many years suggests that treatments during its earliest stage when

adults manifest normal cognitive function may offer the best chance of preventing future

cognitive impairment. However, this opportunity requires the identification of at-risk

older adults who are likely to benefit from early interventions. Our current findings lend

further support for accumulating evidence that Alzheimer's disease affects diverse

cognitive and other non-cognitive aging phenotypes such as physical frailty and

sarcopenia [6, 10, 12, 42]. Thus, our findings are timely as they inform on how to

optimize the construction of models to identify at risk older adults by including a wider

array of motor, cognitive and behavioral metrics [1, 2, 43, 44]. To date there is no

consensus about whether cognitive function metrics can or should be included together

with non-cognitive function metrics for predicting Alzheimer's dementia. The current

results demonstrate the importance of addressing this issue since including cognitive

function metrics can impact model performance and the value added for non-cognitive

measures used to construct risk models for different Alzheimer's cognitive phenotypes.

Examining important predictive covariates selected in our Cox risk models

highlights the importance of motor function (e.g., hand strength and Parkinsonian gait

score) as one of the most important non-cognitive covariates in predicting both incident

Alzheimer's dementia and incident cognitive impairment. Although our previous study

showed that when cognitive metrics are considered motor function did not show

incremental predictivity for Alzheimer's dementia [45], this study showed that motor

metrics provide additional predictive information for both Alzheimer's dementia and

cognitive impairment (**Fig 2; Supplementary Table 5**). Motor planning and ongoing

attention is necessary for all movement. Thus, the fact that "we must think first and then

move next" may explain why motor metrics predict cognitive impairment. Yet

conventional motor testing only quantifies movement and does not assess specific

cognitive indices underlying motor planning or executive and attentional resources

crucial for movement execution. Instrumented gait testing with unobtrusive sensors can

be used to quantify cognitive mobility metrics which precede movement [46, 47]. Further

work is needed to determine if adding additional cognitive mobility metrics may improve

predictions of adults at risk for Alzheimer's dementia and cognitive impairment.

Also, broadening the motor metrics used to predict cognitive impairment might

help circumvent statistical concerns about confounding predictors with model outcomes

as cognitive mobility metrics are not part of current cognitive batteries used to document

dementia or cognitive impairment. While there are many knowledge gaps in our

understanding of the trajectory for the accumulation of AD pathology, the time course

for β-amyloid and tau-tangles during the early and later stages of Alzheimer's disease

may vary; so fluid biomarkers of AD traits might be particularly helpful for improving

model performance [34, 48]. Finally, leveraging the rapid advances in machine learning

suggests that it may be possible to impute and include underlying AD pathologies to

improve model performances [23, 49-53].

Strength & Limitations

The study has several strengths that lend confidence for the current findings. All

subjects were recruited from the community, underwent an annual detailed clinical

evaluation, and were determined to be free of dementia at study entry. Large numbers

of men and women underwent annual assessments, and follow-up rates were very high.

Uniform, structured procedures were followed that enhanced stability of diagnoses

across time, space, and examiners. Diverse non-cognitive covariates were examined.

An important strength of the current study design is that we compared the performances

of models predicting cognitive impairment and Alzheimer's dementia in the same

individuals with identical covariates [54]. Moreover, we were able to replicate our results

in an independent sample of older adults who underwent the same assessments and

testing by the same staff. However, further studies will be needed due to limitations.

Participants were predominantly Americans of European descent and have higher than

average levels of education, so our findings will need to be replicated in more diverse

populations. Brain imaging and fluid biomarkers were not examined. While we

employed the NIA-AA criterion for clinical diagnosis of Alzheimer's dementia, we

recognize that this diagnosis is often associated with mixed brain pathologies as shown

in our analysis of decedents who underwent brain autopsy. The particular cognitive

battery employed is more extensive than what might be available outside of a research

setting highlighting the importance of our findings using the MMSE.

Acknowledgments

This work was supported by the National Institute of Health R35GM138313,

P30AG10161, K01AG054700, R01AG15819, R01AG17917, R01AG56352; the Illinois

Department of Public Health; and the Robert C. Borwell Endowment Fund. The funding

organizations had no role in the design or conduct of the study; collection, management,

analysis, or interpretation of the data; or preparation, review, or approval of the

manuscript. We are deeply indebted to all participants who contributed their data and

agreed to autopsy at the time of their death. We are thankful to the staff at the Rush

Alzheimer's Disease Center.

Disclosure Statement

The authors have no conflict of interest to report.

References

[1]   Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. *Lancet* **377**, 1019-1031.

[2]   Burns A, Iliffe S (2009) Alzheimer's disease. *BMJ* **338**, b158.

[3]   Jack CR, Jr., Albert M, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to revised criteria for the diagnosis of Alzheimer's disease: National Institute on Aging and the Alzheimer's Association workgroup. *Alzheimers Dement* **7**, 256-262.

[4]   Barnes DE, Lee SJ (2011) Predicting Alzheimer's risk: why and how? *Alzheimer's Research & Therapy* **3**, 33.

[5]   Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2010) A summary risk score for the prediction of Alzheimer disease in elderly persons. *Arch Neurol* **67**, 835-841.

[6]   Albers MW, Gilmore GC, Kaye J, Murphy C, Wingfield A, Bennett DA, Boxer AL, Buchman AS, Cruickshanks KJ, Devanand DP, Duffy CJ, Gall CM, Gates GA, Granholm AC, Hensch T, Holtzer R, Hyman BT, Lin FR, McKee AC, Morris JC, Petersen RC, Silbert LC, Struble RG, Trojanowski JQ, Verghese J, Wilson DA, Xu S, Zhang LI (2015) At the interface of sensory and motor dysfunctions and Alzheimer's disease. *Alzheimers Dement* **11**, 70-98.

[7]   Buchman AS, Schneider JA, Wilson RS, Bienias JL, Bennett DA (2006) Body mass index in older persons is associated with Alzheimer disease pathology. *Neurology* **67**, 1949-1954.

[8]   Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA (2005) Change in body mass index and risk of incident Alzheimer disease. *Neurology* **65**, 892-897.

[9]   Yu L, Boyle PA, Leurgans SE, Wilson RS, Bennett DA, Buchman AS (2019) Incident Mobility Disability, Mild Cognitive Impairment, and Mortality in Community-Dwelling Older Adults. *Neuroepidemiology*, 1-8.

[10]   Beeri MS, Leugrans SE, Delbono O, Bennett DA, Buchman AS (2021) Sarcopenia is associated with incident Alzheimer's dementia, mild cognitive impairment, and cognitive decline. *J Am Geriatr Soc.*

[11]   Buchman AS, Bennett DA (2022) Mixed Neuropathologies, Neural Motor Resilience and Target Discovery for Therapies of Late-Life Motor Impairment. *Front. Hum. Neurosci.* **16**, 853330.

[12]   MacDonald SW, Hundza S, Love JA, DeCarlo CA, Halliday DW, Brewster PW, Lukyn TV, Camicioli R, Dixon RA (2017) Concurrent Indicators of Gait Velocity and Variability Are Associated with 25-Year Cognitive Change: A Retrospective Longitudinal Investigation. *Front Aging Neurosci* **9**, 17.

[13]   Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA (2018) Religious Orders Study and Rush Memory and Aging Project. *J Alzheimers Dis* **64**, S161-S189.

[14]   Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J (2002) Natural history of mild cognitive impairment in older persons. *Neurology* **59**, 198-205.

[15]   Park M, Buchman AS, Lim AS, Leurgans SE, Bennett DA (2014) Sleep complaints and incident disability in a community-based cohort study of older persons. *Am J Geriatr Psychiatry* **22**, 718-726.

[16] Buchman AS, Yu L, Oveisgharan S, Petyuk VA, Tasaki S, Gaiteri C, Wilson RS, Grodstein F,
Schneider JA, Klein H-U, De Jager PL, Bennett DA (2021) Cortical proteins may provide
motor resilience in older adults. *Scientific Reports* **11**, 11311.
[17] Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive
review. *J Am Geriatr Soc* **40**, 922-935.
[18] Cox DR (1972) Regression models and life‐tables. *Journal of the Royal Statistical
Society: Series B (Methodological)* **34**, 187-202.
[19] Benichou J, Gail MH (1990) Estimates of absolute cause-specific risk in cohort studies.
Biometrics **46**, 813-826.
[20] Gerds TA, Scheike TH, Andersen PK (2012) Absolute risk regression for competing risks:
interpretation, link functions, and prediction. *Stat Med* **31**, 3921-3930.
[21] Ozenne B, Sørensen AL, Scheike T, Torp-Pedersen C, Gerds TA (2017) riskRegression:
predicting the risk of an event using Cox regression models. *The R Journal* **9**, 440-460.
[22] Linden A (2006) Measuring diagnostic and predictive accuracy in disease management:
an introduction to receiver operating characteristic (ROC) analysis. *J Eval Clin Pract* **12**,
132-139.
[23] Hastie T, Tibshirani R, Friedman JS (2009) *The Elements of Statistical Learning*, Springer-
Verlag New York.
[24] DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or
more correlated receiver operating characteristic curves: a nonparametric approach.
Biometrics **44**, 837-845.
[25] Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test
assessment. *J Thorac Oncol* **5**, 1315-1316.
[26] D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB
(2008) General cardiovascular risk profile for use in primary care: the Framingham Heart
Study. *Circulation* **117**, 743-753.
[27] Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J (2006) Risk
score for the prediction of dementia risk in 20 years among middle aged people: a
longitudinal, population-based study. *Lancet Neurol* **5**, 735-741.
[28] Walters K, Hardoon S, Petersen I, Iliffe S, Omar RZ, Nazareth I, Rait G (2016) Predicting
dementia risk in primary care: development and validation of the Dementia Risk Score
using routinely collected data. *BMC Med* **14**, 6.
[29] Vos SJB, van Boxtel MPJ, Schiepers OJG, Deckers K, de Vugt M, Carrière I, Dartigues JF,
Peres K, Artero S, Ritchie K, Galluzzo L, Scafato E, Frisoni GB, Huisman M, Comijs HC,
Sacuiu SF, Skoog I, Irving K, O'Donnell CA, Verhey FRJ, Visser PJ, Köhler S (2017)
Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-
Old: Validation of the LIBRA Index. *J Alzheimers Dis* **58**, 537-547.
[30] Li J, Ogrodnik M, Devine S, Auerbach S, Wolf PA, Au R (2018) Practical risk score for 5-,
10-, and 20-year prediction of dementia in elderly persons: Framingham Heart Study.
Alzheimers Dement **14**, 35-42.
[31] Anstey KJ, Cherbuin N, Herath PM, Qiu C, Kuller LH, Lopez OL, Wilson RS, Fratiglioni L
(2014) A self-report risk index to predict occurrence of dementia in three independent
cohorts of older adults: the ANU-ADRI. *PLoS One* **9**, e86141.

[32] van Middelaar T, Hoevenaar-Blom MP, van Gool WA, Moll van Charante EP, van Dalen
JW, Deckers K, Kohler S, Richard E (2018) Modifiable dementia risk score to study
heterogeneity in treatment effect of a dementia prevention trial: a post hoc analysis in
the preDIVA trial using the LIBRA index. *Alzheimers Res Ther* **10**, 62.
[33] Belleville S, Fouquet C, Hudon C, Zomahoun HTV, Croteau J, Consortium for the Early
Identification of Alzheimer's d-Q (2017) Neuropsychological Measures that Predict
Progression from Mild Cognitive Impairment to Alzheimer's type dementia in Older
Adults: a Systematic Review and Meta-Analysis. *Neuropsychol Rev* **27**, 328-353.
[34] Albert M, Zhu Y, Moghekar A, Mori S, Miller MI, Soldan A, Pettigrew C, Selnes O, Li S,
Wang MC (2018) Predicting progression from normal cognition to mild cognitive
impairment for individuals at 5 years. *Brain* **141**, 877-887.
[35] Lin HR, Tsuji T, Kondo K, Imanaka Y (2018) Development of a risk score for the prediction
of incident dementia in older adults using a frailty index and health checkup data: The
JAGES longitudinal study. *Prev Med* **112**, 88-96.
[36] Pankratz VS, Roberts RO, Mielke MM, Knopman DS, Jack CR, Jr., Geda YE, Rocca WA,
Petersen RC (2015) Predicting the risk of mild cognitive impairment in the Mayo Clinic
Study of Aging. *Neurology* **84**, 1433-1442.
[37] Steenland K, Zhao L, John SE, Goldstein FC, Levey A, Alvaro A, Alzheimer's Disease
Neuroimaging I (2018) A 'Framingham-like' Algorithm for Predicting 4-Year Risk of
Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using
Multidomain Information. *J Alzheimers Dis* **63**, 1383-1393.
[38] Fouladvand S, Mielke MM, Vassilaki M, Sauver JS, Petersen RC, Sohn S (2019) Deep
Learning Prediction of Mild Cognitive Impairment using Electronic Health Records.
Proceedings (IEEE Int Conf Bioinformatics Biomed) **2019**, 799-806.
[39] Patnode CD, Perdue LA, Rossom RC, Rushkin MC, Redmond N, Thomas RG, Lin JS (2020)
Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and
Systematic Review for the US Preventive Services Task Force. *Jama* **323**, 764-785.
[40] Zammit AR, Yu L, Petyuk V, Schneider JA, De Jaeger PL, Klein H-U, Bennett DA, Buchman
AS (2022) Aggregation of cortical resilience proteins yields person-specific indices of
cognitive resilience. *Neurology* **In Press**.
[41] García-Ptacek S, Faxén-Irving G, Cermáková P, Eriksdotter M, Religa D (2014) Body mass
index in dementia. *Eur J Clin Nutr* **68**, 1204-1209.
[42] Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA (2007) Frailty is Associated With
Incident Alzheimer's Disease and Cognitive Decline in the Elderly. *Psychosomatic
Medicine* **69**, 483-489.
[43] Jack CR, Bennett DA, Blennow K (2018) 2018 NIA-AA research framework to investigate
the Alzheimer's disease continuum.
[44] Montero-Odasso M, Pieruccini-Faria F, Ismail Z, Li K, Lim A, Phillips N, Kamkar N, Sarquis-
Adamson Y, Speechley M, Theou O, Verghese J, Wallace L, Camicioli R (2020) CCCDTD5
recommendations on early non cognitive markers of dementia: A Canadian consensus.
Alzheimers Dement (N Y) **6**, e12068.
[45] Beeri MS, Leurgans SE, Bennett DA, Barnes LL, Buchman AS (2021) Diverse Motor
Performances Are Related to Incident Cognitive Impairment in Community-Dwelling
Older Adults. *Front Aging Neurosci* **13**, 717139.

[46] Gazit E, Buchman AS, Dawe R, Curran TA, Mirelman A, Giladi N, Hausdorff JM (2020)
What happens before the first step? A New Approach to Quantifying Gait Initiation
Using a Wearable Sensor. *Gait Posture* **76**, 128-135.
[47] Bayot M, Dujardin K, Tard C, Defebvre L, Bonnet CT, Allart E, Delval A (2018) The
interaction between cognition and motor control: A theoretical framework for dual-task
interference effects on posture, gait initiation, gait and turning. *Neurophysiol Clin* **48**,
361-375.
[48] Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M (2019)
Progression to dementia in memory clinic patients with mild cognitive impairment and
normal beta-amyloid. *Alzheimers Res Ther* **11**, 99.
[49] Zou H, Hastie T (2005) Regularization and variable selection via the elastic net. *Journal of
the Royal Statistical Society: Series B (Statistical Methodology)* **67**, 301-320.
[50] Nagpal S, Meng X, Epstein MP, Tsoi LC, Patrick M, Gibson G, De Jager PL, Bennett DA,
Wingo AP, Wingo TS, Yang J (2019) TIGAR: An Improved Bayesian Tool for
Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits. *Am J Hum
Genet* **105**, 258-266.
[51] Luningham JM, Chen J, Tang S, De Jager PL, Bennett DA, Buchman AS, Yang J (2020)
Bayesian Genome-wide TWAS Method to Leverage both cis- and trans-eQTL Information
through Summary Statistics. *Am J Hum Genet* **107**, 714-726.
[52] Tang S, Buchman AS, De Jager PL, Bennett DA, Epstein MP, Yang J (2021) Novel
Variance-Component TWAS method for studying complex human diseases with
applications to Alzheimer's dementia. *PLoS Genet* **17**, e1009482.
[53] Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, Dammer EB, Robins C,
Beach TG, Reiman EM, Epstein MP, De Jager PL, Lah JJ, Bennett DA, Seyfried NT, Levey
AI, Wingo TS (2021) Integrating human brain proteomes with genome-wide association
data implicates new proteins in Alzheimer's disease pathogenesis. *Nat Genet* **53**, 143-
146.
[54] Licher S, Yilmaz P, Leening MJG, Wolters FJ, Vernooij MW, Stephan BCM, Ikram MK,
Ikram MA (2018) External validation of four dementia prediction models for use in the
general community-dwelling population: a comparative analysis from the Rotterdam
Study. *Eur J Epidemiol* **33**, 645-655.
686
687

Table 1. Select clinical characteristics of the analytic cohort at baseline (n=1179 in MAP; n=1103 in ROS).

Group	Variable	Mean (SD) or N (%)
Demographics and Common Alzheimer's Risk Factors	Mild cognitive impairment (N)	541 (23.7)
	Follow-up years (2-26)	8 (5.42)
	Age (years, 53-102)	77.4 (7.51)
	Sex (males, N)	577 (25.2)
	Education (years, 0-30)	16.5 (3.65)
	BMI (9.09, 62.91)	27.52 (5.50)
	MMSE Score (18-30)	28.37 (1.73)
	APOE E2 (carriers, N)	330 (14.4)
	APOE E4 (carriers, N)	513 (22.4)
Covariates Uniquely Profiled by ROS/MAP	Composite cognition test Z-score (-1.95, 1.47)	0.32 (0.51)
	Physical activity (0-35)	3.19 (3.79)
	Social network size (0, 162)	7.58 (7.52)
	Maternal education (years, 0-20)	9.66 (3.79)
	Paternal education (years, 0-24)	9.60 (4.26)
	Anxiety (0-10)	1.28 (1.69)
	Proneness to psychological distress (0-42)	15.69 (6.44)
	Tendency to be social, active, and optimistic (5, 24)	15.52 (3.14)
	Early life socioeconomic status Z-score (-2.72, 2.15)	0.02 (0.74)
	Anger (0-10)	1.76 (1.88)
	TOMM40_S (N)	1,126 (49.2)
	TOMM40_L (N)	371 (16.2)
	TOMM40_VL (N)	1,114 (48.7)
Motor Metrics	Dexterity (0, 1.85)	1.02 (0.16)
	Gait function (0, 2.13)	1.05 (0.27)
	Hand strength (0, 2.36)	1.07 (0.30)
	Bradykinesia (0, 85)	8.82 (10.6)
	Parkinsonian gait (0, 85.18)	12.16 (13.45)
	Rigidity (0, 60)	2.15 (5.88)
	Tremor (0, 69.69)	2.23 (5.02)
Self-reported Sleep Metrics	Sleep latency (1, 9)	3.63 (1.14)
	Sleep consolidation (1, 8)	2.92 (1.31)
	Daytime sleepiness (1, 5)	3.21 (1.33)
	Sleep quality (1, 5)	2.10 (1.05)

Table 2. Prediction accuracy (with 95% confidence interval), sensitivity, and specificity with respect to selected risk score thresholds that ensure the highest overall accuracy. Values in this table are reflecting risk model prediction performance at one point in the ROC curves as shown in Fig1, with corresponding risk score thresholds. Samples with predicted risk scores greater than the selected threshold were considered as Predicted Positives (incident Alzheimer's dementia or incident cognitive impairment), otherwise Predicted Negatives (not developing Alzheimer's dementia or NCI).

		Model A. Non-Cognitive Covariates		Model B. MMSE + Non-Cognitive Covariates		Model C. MMSE + Composite Cognition + Non-Cognitive Covariates		Model D. Composite Cognition	
		Y3	Y5	Y3	Y5	Y3	Y5	Y3	Y5
NCI/MCI -> Alzheimer's Dementia	**Accuracy[a] (95% CI)**	0.664 (0.637, 0.694)	0.616 (0.586, 0.644)	0.761 (0.735, 0.786)	0.707 (0.679, 0.734)	0.856 (0.834, 0.876)	0.816 (0.792, 0.838)	0.865 (0.844, 0.885)	0.784 (0.758, 0.808)
	Sensitivity[b]	0.810	0.804	0.810	0.804	0.810	0.804	0.810	0.804
	Specificity[c]	0.655	0.591	0.757	0.694	0.860	0.817	0.870	0.781
NCI -> Alzheimer's Dementia	**Accuracy[a] (95% CI)**	0.688 (0.655, 0.719)	0.701 (0.669, 0.732)	0.790 (0.761, 0.818)	0.695 (0.662, 0.726)	0.818 (0.790, 0.844)	0.763 (0.733, 0.791)	0.806 (0.778, 0.832)	0.645 (0.611, 0.677)
	Sensitivity[b]	0.800	0.804	0.800	0.804	0.800	0.804	0.800	0.804
	Specificity[c]	0.685	0.695	0.790	0.689	0.818	0.761	0.806	0.636
NCI -> Cognitive Impairment	**Accuracy[a] (95% CI)**	0.650 (0.617, 0.682)	0.635 (0.601, 0.667)	0.662 (0.629, 0.693)	0.648 (0.614, 0.680)	0.701 (0.669, 0.732)	0.685 (0.679, 0.716)	0.672 (0.639, 0.703)	0.657 (0.624, 0.689)
	Sensitivity[b]	0.700	0.700	0.700	0.700	0.700	0.700	0.700	0.700
	Specificity[c]	0.635	0.604	0.650	0.623	0.702	0.678	0.664	0.636

a. Accuracy= (# True Positive Predictions + # True Negative Predictions) / (# of test samples)
b. Sensitivity = (# True Positive Predictions) / (# Positives in test samples) = True Positive Fraction
c. Specificity = (# True Negative Predictions) / (# Negatives in test samples) = 1 - False Positive Fraction

Figure Legends

Fig 1. ROC plots of risk prediction for incident Alzheimer's dementia and incident cognitive impairment with non-cognitive and cognitive covariates alone and together.
Model A uses 55 non-cognitive covariates; Model B 55 non-cognitive covariates + MMSE; Model C 55 non-cognitive covariates+ MMSE+ Composite Cognition; Model D uses only Composite Cognition.

ROW 1 No dementia (NCI or MCI) at baseline and incident Alzheimer's Dementia: Model B vs A showed significant improvement with p-values=$(4.85 \times 10^{-4}, 1.09 \times 10^{-4})$ for Year (3, 5). Model C vs B showed significant improvement with p-values=$(7.55 \times 10^{-7}, 9.15 \times 10^{-6})$ for Year (3, 5). Model C vs D for Year 3 (p-value = 0.156) but significant improvement for Year 5 (p-value = 0.033).

ROW 2 NCI at baseline and incident Alzheimer's Dementia: Model B vs A showed significant improvement only for Year 3 with p-value=0.042 but not for Year 5 with p-value=0.185. Model C vs A/B showed significant improvement p-values=~(0.004, 0.019) for Year (3, 5). Model C vs D showed comparable performance for Year 3 with p-value=0.156 but significant improvement for Year 5 with p-value=0.025.

ROW 3 NCI and incident cognitive impairment: Model B vs A showed significant improvement p-values p-values=(0.002, 0.008) for Year (3, 5). Model C vs B showed significant improvement p-values=(0.001, 0.001) for Year (3, 5). Model C vs D showed significant improvement p-values=(0.029, 0.002) for Year (3, 5).

Fig 2. Important predictive covariates predicting incident Alzheimer's dementia and incident cognitive impairment.

ROW 1 No dementia (NCI or MCI) at baseline and incident Alzheimer's Dementia: Age and APOE E4 allele were identified as the top positive risk factors in all three models. Hand strength was the top protective factor in Model A when no cognitive covariates were considered. MMSE was the top protective factor in Model B when composite cognition was not considered. Composite cognition score was the top protective factor in Model C where all clinical covariates were considered.

ROW 2 NCI at baseline and incident Alzheimer's Dementia: Age was identified as the top positive risk factor in all three models. Motor gait and hand strength were top protective factor in Model A and Model B when composite cognition score was not considered. Instead of composite cognition score, vascular disease history at baseline was the top "protective" factor in Model C, which might lead to death before the development of Alzheimer's dementia.

ROW 3 NCI and incident cognitive impairment: Age and education were identified as top positive risk factors in all three models, where education years were positively correlated with the number of follow-up years in ROS/MAP. Hand strength and social network size were top protective factor in Model A when no cognitive covariates were considered. MMSE was the top protective factor in Model B when composite cognition was not considered. Composite cognition score was the top protective factor in Model C where all clinical covariates were considered.